Publications by authors named "Christine P Molnar"
Objectives: This study compared machine learning models using unimodal imaging measures and combined multi-modal imaging measures for deep brain stimulation (DBS) outcome prediction in treatment resistant depression (TRD).
Methods: Regional brain glucose metabolism (CMRGlu), cerebral blood flow (CBF), and grey matter volume (GMV) were measured at baseline using 18F-fluorodeoxy glucose (18F-FDG) positron emission tomography (PET), arterial spin labelling (ASL) magnetic resonance imaging (MRI), and T1-weighted MRI, respectively, in 19 patients with TRD receiving subcallosal cingulate (SCC)-DBS. Responders ( = 9) were defined by a 50% reduction in HAMD-17 at 6 months from the baseline.
Background And Objective: Pathogenic variants in KCNT1 have been associated with severe forms of epilepsy, typically sleep-related hypermotor epilepsy or epilepsy of infancy with migrating focal seizures. To show that pathogenic variants in KCNT1 can be associated with mild extra-frontal epilepsy, we report a KCNT1 family with a wide spectrum of phenotypes ranging from developmental and epileptic encephalopathy to mild focal epilepsy without cognitive regression and not consistent with sleep-related hypermotor epilepsy.
Methods: A large Canadian family of Caucasian descent including 9 affected family members was recruited.
Article Synopsis
- The study examined how ISSPECT and PET imaging contribute to decision-making in epilepsy surgery for patients with resistant focal epilepsy.
- About 106 patients were analyzed, revealing that concordance with clinical consensus was higher for ISSPECT (76%) than for PET (79%), but both were important in evaluating surgical options.
- The findings suggest that concordance with PET imaging increases the likelihood of proceeding to further monitoring, while concordance with ISSPECT and MRI correlates with better surgical outcomes.
Subcallosal cingulate (SCC) deep brain stimulation (DBS) is a promising therapy for treatment-resistant depression (TRD), but response rates in open-label studies were not replicated in a large multicenter trial. Identifying biomarkers of response could improve patient selection and outcomes. We examined SCC metabolic activity as both a predictor and marker of SCC DBS treatment response.
View Article and Find Full Text PDFBackground: Metastatic head and neck squamous cell carcinoma with an unknown primary is an uncommon but important problem. PET/CT, as an adjunct to diagnosis, is potentially useful but has never been studied in a prospective, single-blinded clinical trial.
Methods: In all, 20 subjects with cervical metastases from an unknown head and neck primary were enrolled in a prospective clinical trial.